Docetaxel
2400-01A
Phase 2 small_molecule active
Quick answer
Docetaxel for Castration-Resistant Prostatic Cancer is a Phase 2 program (small_molecule) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck KGaA, Darmstadt, Germany
- Indication
- Castration-Resistant Prostatic Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active